Last reviewed · How we verify
High Dose Trivalent Influenza Vaccine
High-dose trivalent influenza vaccine stimulates a stronger immune response by delivering increased antigen quantities to enhance antibody production and cellular immunity against three influenza virus strains.
A high-dose formulation of trivalent influenza vaccine that stimulates a stronger immune response by delivering increased antigen quantities to enhance antibody production and cellular immunity against three influenza virus strains. Used for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in immunocompromised populations.
At a glance
| Generic name | High Dose Trivalent Influenza Vaccine |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains three inactivated influenza virus strains (typically two A subtypes and one B type) at higher antigen concentrations than standard-dose formulations. This increased antigenic load triggers more robust activation of B cells and T cells, leading to higher titers of neutralizing antibodies and improved cell-mediated immunity, particularly beneficial in older adults with waning immune responses.
Approved indications
- Prevention of influenza A and B in adults aged 65 years and older
- Prevention of influenza in immunocompromised populations
Common side effects
- Injection site soreness
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older (PHASE1)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: